Eli Chapman, PhD

Assistant Professor
Pharmacology & Toxicology

FAX: 520-626-2466
Pharmacy (Skaggs) Building 414

In the Chapman laboratory, we are generally interested in developing methodologies to facilitate drug discovery, using chemical biology to study the complex biochemistry and biophysics of protein quality control machinery, and using our chemical and biological tools to discover and study selective inhibitors of medically relevant targets. Students and fellows within our program are engaged in a truly multi-disciplinary effort providing a unique fusion between natural products chemistry, medicinal chemistry, organic synthesis, molecular biology, biochemistry and cellular biology – chemical biology. Our research can be divided into three broad areas:

a) Protein-guided therapeutic discovery. Although proteins are often the primary targets of therapeutic agents, their use often comes very late in the drug discovery process. This is especially true in the discovery of natural product-based therapeutics. We now seek to change this by introducing the protein or proteins of interest at an early stage of the discovery process. Employing a simple concept, long used in cellular and molecular biology, we aim to develop a new platform to discover natural products from marine and terrestrial sources, with future pharmacological potential. This platform will use a protein of interest, based on pharmaceutical potential, linked to a solid support to capture natural products from diverse collectives of purified products and lysates. The captured natural products will then be identified and characterized using state-of-the-art micro-analytical techniques followed by biochemical and cell-biological analysis. This platform will be coupled with the tools of structural genomics to allow access to proteins implicated in many different pathological states. It will also eliminate assay bias and look only for binding, providing a platform to discover natural products with truly novel modes of action, even for traditionally ‘undruggable’ targets.

b) Chemical biology to study p97 biochemistry and biophysics. The ATPase associated with various cellular activities (AAA+) chaperone, p97, is an amazing member of this family. It is a nearly 600 kDa machine that harnesses the energy of ATP-binding and hydrolysis to affect a large and diverse collective of biological functions (i.e. endoplasmic reticulum asscoiated degradation, homotypic membrane fusion, cell-cycle regulation, etc.) and is implicated in numerous pathological states ranging from cancer to neurodegenerative proteinopathies (i.e. Huntington’s disease, ALS, Alzheimer’s disease, etc.). Understanding the underpinnings of these diverse and varied functions and how these correlate with pathological states will provide insight into the disease and guide future drug development efforts. To this end, we are developing a cadre of chemical biology tools to facilitate biochemical and biophysical studies and unfold a detailed mechanistic picture of p97.

c) Small-molecule based therapeutic discovery and development. The University of Arizona has a unique niche in drug discovery with a diverse collective of small-molecules, unique chemistries, and a number of high throughput discovery and development platforms in place. We wish to exploit this expertise and these resources to discover small-molecule inhibitors of two proteins for which we have developed chemical biology tools and biophysical assays that will directly translate to medium to high-throughput small-molecule discovery. The first is p97, discussed above, and the second is α-synuclein, which is associated with Parkinson’s disease. The biophysical tools we develop will allow for discovery of inhibitors with novel modes of action such as interference with protein-protein interactions and blocking structural rearrangements.


BS Chemistry, University of California at Berkeley, 1996
MA Chemistry, Columbia University, N.Y., 1998
PhD Chemistry, Scripps Research Institute, La Jolla, Calif., 2003


1. Thorson, J. S., Chapman, E., Judice, J. K., Murphy, E. M., and Schultz, P. G. (1995) Linear free energy analysis of hydrogen bonding in proteins. J. Am. Chem. Soc. 117, 1157-1158.

2. Thorson, J. S., Chapman, E., and Schultz, P. G. (1995) Analysis of hydrogen bond strengths in proteins using unnatural amino acids. J. Am. Chem. Soc. 117, 9361-9362.

3. Chapman, E., Thorson, J. S., and Schultz, P. G. (1997) Mutational analysis of backbone hydrogen bonding in Staphylococcal nuclease. J. Am. Chem. Soc. 119, 7151-7152.

4. Leighton, J. L., and Chapman, E. (1997) Rhodium catalyzed silylformylation of alkenes. J. Am. Chem. Soc. 119, 12416-12417.

5. Thorson, J. S., Shin, I., Chapman, E., Stenberg, G., Mannervik, B., and Schultz, P. G. (1998) Analysis of the role of the active site tyrosine in human glutathione transferase A1-1 by unnatural amino acid mutagenesis. J. Am. Chem. Soc. 120, 451-452.

6. Burkart, M. D., Izumi, M., Chapman, E., and Wong, C-H. (2000) Regeneration of PAPS for the enzymatic synthesis of sulfated oligosaccharides. J. Org. Chem. 65, 5565-5574.

7. Chapman, E., and Wong, C-H. (2002) A pH sensitive colorimetric assay for the high-throughput screening of enzyme inhibitors and substrates: a case study using kinases. Bioorg. Med. Chem. 10, 551-555.

8. Chapman, E., Ding, S., Schultz, P. G., and Wong, C-H. (2002) A potent and highly selective sulfotransferase inhibitor. J. Am. Chem. Soc. 124, 14524-14525.

9. Chapman, E., Bryan, M. C., and Wong, C-H. (2003) Mechanistic studies of b-arylsulfotransferase-IV. Proc. Natl. Acad. Sci. USA 100, 910-915.

10. Wong, C-H., Bryan, M. C., Nyffeler, P. T., Liu, H., and Chapman, E. (2003) Synthesis of carbohydrate-based antibiotics.  Pure Appl. Chem. 75, 179.

11. Chapman, E., Best, M. D., Hanson, S. R., and Wong, C-H. (2003) Sulfotransferases: structure, mechanism, biological activity, inhibition, and synthetic utility. Angew. Chem. Int. Ed. 43, 3526-3548.

12. Best, M. D., Brik, A., Chapman, E., Lee, L. V., Cheng, W-C., and Wong, C-H. (2004) Rapid discovery of potent sulfotransferase inhibitors using diversity-oriented reaction in microplates followed by in situ screening. ChemBioChem 5, 811-819.

13. Chapman, E., Farr, G. W., Usaite, R., Furtak, K., Fenton, W. A., Chaudhuri, T. K., Hondorp, E. R., Matthews, R. G., Wolf, S. G., Yates, J. R., Pypaert, M., and Horwich, A. L. (2006) Global aggregation of newly translated proteins in an Escherichia coli strain deficient of the chaperonin GroEL.  Proc. Natl. Acad. Sci. USA 103, 15800-15805.

14. Horwich, A. L.; Fenton, W. A.; Chapman, E.; and Farr, G. W. (2007) Two families of chaperonin: Physiology and Mechanism. Annu. Rev. Cell Dev. Biol. 23, 115-145.

15. Chapman, E.; Fenton, W. A.; Horwich, A. L. (2008) Requirement for binding multiple ATPs to convert a GroEL ring to the folding-active state. Proc. Natl. Acad. Sci. U.S.A. 105, 19205-19210.

16. Chapman*, E.; Farr, G. W.; Furtak, K.; Horwich, A. L. (2009) A small molecule inhibitor selective for a variant ATP-binding site of the chaperonin GroEL. Bioorg. Med. Chem. Lett. 19, 811-813.

17. Chapman*, E.; Fry, A. N.; and Kang, MJ. (2011) The complexities of p97 function in health and disease. Mol. Biosyst. 7, 700-710.

18. Charbon, G., Brustad, E., Scott, K. A., Wang, J., Løbner-Olesen, A., Schultz, P. G., Jacobs-Wagner, C., and Chapman*, E. (2011) Subcellular protein localization by using a genetically encoded fluorescent amino Acid. Chembiochem. 12, 1818-1821.

19. Charbon, G.; Wang, J.; Brustad, E.; Schultz, P. G.; Horwich, A. L.; Jacobs-Wagner, C.; and Chapman*, E. (2011) Localization of GroEL determined by in vivo incorporation of a fluorescent amino acid. Bioorg. Med. Chem. Lett., 21, 6067-6070.

20. Chapman*, E.; and Hanson*, S. R. (2011) Sulfotransferases and Sulfatases: Sulfate modification of Carbohydrates. In Carbohydrate-Modifying Biocatalysts (Grunwald, P., Ed.), Pan Stanford Publishing Pte. Ltd., Singapore, 329-396.

Originally posted: September 9, 2013
Last updated: May 12, 2016
Want to update? Contact Webmaster
Share This